




OPEN ACCESS

Original research

# Double-blinded randomised placebo controlled trial of enterogel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D)

Carol Angela Howell <sup>1</sup>, Anu Kemppinen,<sup>2</sup> Victoria Allgar,<sup>3</sup> Matthew Dodd,<sup>4</sup> Charles H Knowles,<sup>5</sup> John McLaughlin,<sup>6,7</sup> Preeti Pandya,<sup>8</sup> Peter Whorwell,<sup>9</sup> Elena Markaryan,<sup>1</sup> Yan Yiannakou<sup>10,11</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2022-327293>).

For numbered affiliations see end of article.

## Correspondence to

Professor Yan Yiannakou, Department of gastroenterology, County Durham and Darlington NHS Foundation Trust, Darlington, Darlington, UK; [yan.yiannakou@nhs.net](mailto:yan.yiannakou@nhs.net)

Received 3 March 2022  
Accepted 12 June 2022

## ABSTRACT

**Objective** Irritable bowel syndrome with diarrhoea (IBS-D) is a common and challenging condition that significantly reduces quality of life. Enterogel (polymethylsiloxane polyhydrate) is an intestinal adsorbent which sequesters harmful molecules and is safe and effective in acute infective diarrhoea. This randomised controlled multicentre trial aimed to investigate its safety and efficacy in patients with IBS-D.

**Design** After a 2-week screening phase, participants were randomised into an 8-week double-blind phase, followed by an 8-week open-label and follow-up phase. Participants recorded stool consistency, pain and global symptoms in e-diaries and questionnaires. The primary outcome was the percentage of responders on a composite abdominal pain ( $\geq 30\%$  decrease in the weekly score) and stool consistency (50% reduction in days per week with at least one stool of BSFS type 6 or 7) score during at least 4 weeks of the treatment period.

**Results** 440 patients with IBS-D were randomised to the double-blind phase with 393 continuing to the open-label phase. The Primary outcome responder rate by intention-to-treat for enterogel versus placebo was 37.4% vs 24.3% (OR 1.95, NNT 8,  $p=0.002$ ). Enterogel also improved stool consistency (48.5% vs 32.5%,  $p<0.0001$ ) abdominal pain (53.3% vs 40.2%,  $p=0.003$ ), stool frequency (treatment effect  $-0.32$  ( $-0.62$  to  $-0.02$ )) and urgency (treatment effect  $-0.59$  ( $-0.85$  to  $-0.33$ )). 60% of patients reported adequate relief of symptoms after open-label treatment. Adverse event frequency was similar in both groups, with no serious events attributable to enterogel.

**Conclusion** Enterogel is safe and effective in IBS-D, providing an alternative to the limited current treatment options.

**Trial registration number** ISRCTN17149988.

## INTRODUCTION, BACKGROUND AND OBJECTIVES

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care.<sup>1</sup> The condition is categorised by symptoms of

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Current treatments for irritable bowel syndrome (IBS) focus on symptom control and satisfaction with treatment is low.
- ⇒ Based on previous small studies in IBS and other conditions, enterogel maybe beneficial for the treatment of IBS-D symptoms.

## WHAT THIS STUDY ADDS

- ⇒ Enterogel showed significantly higher treatment response rate versus placebo for combined symptoms of abdominal pain and stool consistency.
- ⇒ Enterogel also showed significant treatment benefit for bloating, stool frequency, urgency and adequate relief.
- ⇒ A high percentage of participants reported adequate relief after open-label phase, and 74.1% showed continued treatment benefit during the follow-up phase.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ Enterogel is a readily available over-the-counter treatment option that could improve global symptoms in patients with IBS-D.


abdominal pain or discomfort accompanied with altered bowel habit and bloating.<sup>2,3</sup> According to patients, the most important factors in the symptomatic treatment of diarrhoea predominant IBS (IBS-D) are the relief of diarrhoea, urgency and abdominal pain. Studies have shown that patients with IBS-D have a significantly higher median pain episode frequency per month,<sup>4</sup> greater stool frequency and looser stool consistency<sup>5</sup> and urgency,<sup>6</sup> than other subtypes.

IBS is a heterogeneous disorder which makes management challenging, with IBS-D therapies focusing on treating predominant symptoms. Recent guidelines<sup>1</sup> recommend patients with IBS are provided with dietary advice and take regular exercise. Other approaches for IBS-D include psychological interventions, the low FODMAP diet, multistrain probiotics and pharmacological interventions. However, evidence to support their



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Howell CA, Kemppinen A, Allgar V, et al. Gut Epub ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2022-327293




**Figure 1** Study design. After a 2-week screening phase, eligible participants were randomised in the 8 week double-blind treatment phase where participants received either placebo or Enterogel, followed by the open-label phase where all participants received Enterogel. Participants who answered Yes for adequate relief at the end of the open-label phase, were included in the 8 week follow-up phase. "Ar" Q, adequate relief question; DB, double-blind; EOT, end of trial; OL, open-label; SP, screening phase.

use is mixed with some drugs providing only poor relief of all IBS symptoms or have safety concerns. More effective therapies are required as less than one third of patients with IBS are satisfied with their current therapy<sup>7</sup> and 34% report no symptom control.<sup>8</sup>

Intestinal adsorbents such as diosmectite a mineral clay, which are classified as medical devices as they have no pharmacological action, have shown promise for the treatment of gastrointestinal conditions including IBS.<sup>9,10</sup> The basis for their use in IBS is not completely understood but is likely due to their capacity to adsorb endogenous and exogenous substances such as bacterial break-down products (eg, lipopolysaccharides), immune proteins and bile acids, thereby inactivating their effects in the gut.

Enterogel is a CE certified over-the-counter (OTC) intestinal adsorbent currently indicated for acute diarrhoea and chronic diarrhoea associated with IBS-D. It can bind bacterial products, bile acids and other harmful substances in the gastrointestinal tract.<sup>11</sup> A recent UK study has shown its effectiveness in acute diarrhoea in adults,<sup>12</sup> however, to date studies have not included a placebo control. Our aim was to investigate the efficacy, tolerability and safety of Enterogel as a treatment for IBS-D symptoms, through a robust, pragmatic multicentre randomised placebo-controlled study.



**Figure 2** SEM image of the porous surface of polymethylsiloxane polyhydrate xerogel.

## METHODS

### Trial design

A multicentre, parallel arm, randomised, double-blind, placebo controlled trial design was used to evaluate the efficacy, tolerability and safety of Enterogel in the treatment of IBS-D in adults.<sup>13</sup> The study was designed in line with FDA guidance for clinical trials in IBS,<sup>14</sup> which allows direct comparison with other products. Following a 2-week screening phase, eligible subjects were randomised to receive either enterogel or placebo for 8 weeks. An incremental dosage schedule was employed starting at 15 g two times a day for the first 5 days, working up to 30 g three times per day, depending on symptom relief. Following the double-blind phase, all participants received open-label enterogel treatment for 8 weeks, followed by a return to standard care; however, those who responded to open-label treatment received a follow-up call 8 weeks later. Initially, there were four face-to-face visits (week -2, 0, 8 and 16) with additional telephone visits at week 2 to ensure compliance, and at week 24 at the end of the follow-up phase (figure 1). Participants recorded symptoms in an electronic or paper diary daily from screening visit until end of open-label phase.

Adult patients aged 16–75 years diagnosed with IBS-D were initially recruited at 14 primary, 13 secondary care sites and a private clinic located across England, with the first participant enrolled on 20 November 2018. The study was suspended due to COVID-19 in March 2020 and the protocol amended to allow remote visits to enable enrolled subjects to continue and the recruitment of new participants. The National Institute for Health and Care Research (NIHR) Patient Recruitment Centre—Newcastle, was converted to a virtual site, recruiting via the ContactME-IBS registry, from anywhere in the UK.


### Participants

Patients were required to meet the Rome IV criteria for IBS-D.<sup>15</sup> Exclusion criteria were: previously diagnosed coeliac disease, inflammatory bowel disease, bowel cancer or bowel resection, other gastrointestinal disorder contributing to the diarrhoea, unexplained weight loss or rectal bleeding, use of probiotic supplements, other intestinal adsorbents, slow-release medications or strong opioids,<sup>16</sup> previous use of enterogel and average abdominal pain score of <3 during screening, this was reduced to <2.5 in response to screening failures after 44% of participants were recruited. Patients who had been on a stable dose of antidepressant for at least 6 weeks were eligible. All female patients of childbearing potential were required to provide a negative pregnancy test at baseline and continue contraception use. Patients were not allowed to take loperamide during the screening period, but after randomisation loperamide was provided as a rescue medication.

### Investigational medical device

Enterogel is a CE certified class IIa medical device composed of polymethylsiloxane polyhydrate and 30% water by weight. The porous hydrogel is amorphous thus insoluble in water, with pores 2–100 nm in diameter, and a large surface area with highest adsorption capacity towards larger molecular weight molecules (figure 2).

Enterogel is a colourless gel and achieving an identical placebo proved challenging. Any gel-like substances used as a placebo could potentially have an effect in the gut; their use as a placebo would require separate validation. Dilution with 200 mL water adequately disguised the active component but the



**Figure 3** Study CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials; ITT, intention-to-treat; LTFU, lost to follow-up; PP, per-protocol.

volume and weight of packaging was excessive. Thus, blinded enterosgel was prediluted in tubes containing 15 g enterosgel (Bioline Products s.r.o., Czech Republic) in 67.5 mL potable water, forming a tasteless, colourless slightly opaque liquid, with 90 mL water used as the placebo comparator. To maintain blinding, Enterosgel and placebo were packaged into identical, opaque, study-specific labelled tubes, which were mixed in 100 mL water by patients before administration. For the open-label phase, OTC enterosgel 15 g sachets were provided.

### Data collection

Participant baseline demographics and medical information were collected at screening visit (week -2). From week -2 to 16, participants completed a daily e-diary to record stool consistency (BSFS), abdominal pain (score 0=no pain at all, score 10=worst possible pain patient can imagine), bowel movements and doses of study treatment and a weekly diary to record adequate relief

over the last week, urgency and bloating score (score 0=not at all, 6=a very great deal) and loperamide use. Participants also completed weekly IBS Severity Scoring System (IBS-SSS)<sup>17</sup> and Work Productivity and Activity Impairment<sup>18 19</sup> and 4-weekly IBS Quality of Life (IBS-QOL)<sup>20 21</sup> and Patient Health Questionnaire-12 Somatic Symptom Scale<sup>22</sup> paper questionnaires. Patients who reported adequate relief of IBS symptoms in the last 4 weeks of the open-label period, were included in the follow-up phase.

### Outcomes

The composite primary outcome was the percentage of patients defined as responders for both abdominal pain and stool consistency during at least 4 weeks in the 8-week treatment period.<sup>14 23</sup> An abdominal pain intensity weekly responder was defined as a patient who experienced  $\geq 30\%$  decrease in the weekly average abdominal pain score compared with the screening period. A

**Table 1** Baseline characteristics of study participants in the ITT population

Characteristic	Placebo (n=221)	Enterogel (n=219)
Age, years (IQR)	44.0 (33.3–55.0)	40.0 (29.0–55.0)
Female gender, n (%)	162 (73.3)	161 (73.5)
Ethnicity, n (%)		
Asian/Asian British	4 (1.8)	3 (1.4)
Black/African/Caribbean/Black British	0 (0.0)	1 (0.5)
White	212 (95.9)	213 (97.3)
Mixed	3 (1.4)	1 (0.5)
Other	2 (0.9)	1 (0.5)
Days $\geq 1$ stool of BSFS 6 or 7, (IQR)*†	4.5 (3.5–6.0)	4.4 (3.0–6.0)
Abdominal pain score, (IQR)*	5.1 (4.1–6.4)	5.0 (3.9–6.1)
IBS-SSS score, (SD)	352.3 (80.8)	334.4 (80.3)

\*Collected during screening phase.

†Median number of days per week with at least one stool of BSFS type 6 or 7 BSFS, Bristol Stool Form Scale; IBS-SSS, Irritable Bowel Syndrome Severity Scoring System total score; ITT, intention-to-treat.

stool consistency weekly responder was defined as a patient experiencing a  $\geq 50\%$  reduction in the number of days per week with at least one stool that has a consistency of BSFS type 6 or 7 compared with the screening period.

Secondary outcomes of abdominal pain, stool consistency and frequency, bloating, urgency, loperamide use and questionnaire scores were compared between randomised groups and adjusted for baseline values. Adequate relief was defined by a 'yes' response to the question 'With regard your IBS symptoms, compared with the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms'. At week 24 follow-up, the secondary outcomes were maintenance of treatment benefit and use of enterogel and loperamide.

### Randomisation and blinding

Treatment allocation was masked for both participants and investigators in the double-blind phase. Randomisation used a proprietary tool, built into the restricted access web-based eCRF hosted by Sealed Envelope, to generate a unique code. Investigators sent the code to the Sponsor's unblinded supplies coordinator, who checked against the randomisation code list to obtain treatment allocation and shipped unlabelled treatment to the patient's home. The randomisation algorithm was based on the

minimisation method where treatment allocation was stratified by site.

### Statistical methods

We sought to demonstrate that enterogel treatment improves stool consistency and reduces abdominal pain in patients with IBS-D. Sample size calculation was based on demonstrating superiority for the primary composite outcome with 90% power at 5% significance level. Assuming a placebo response rate of 20% based on previous studies<sup>24,25</sup> and 35% in the active treatment group, 182 patients per treatment group were required. Assuming 15% drop-out rate, we sought to randomise 430 patients. However, due to fewer participants failing the screening phase towards the end of recruitment, we allowed these patients to continue and recruited 440 participants.

Analysis and presentation of data was in accordance with Consolidated Standards of Reporting Trials guidance, using STATA IC V.15.1. Primary analyses were conducted following the intention-to-treat (ITT) principle with patient outcomes analysed according to their original randomised group irrespective of deviations based on non-compliance. Per-protocol (PP) analyses were also performed, where participants who were ineligible at randomisation, did not take any study treatment or provide any primary outcome measures, were excluded. The primary outcome measure was analysed using both observed data and multiple imputation by chained equations to impute missing daily scores. Missing values were imputed on a weekly basis, with the following variables included in the imputation models: treatment group, baseline measure of the outcome, age and sex. The primary outcome was summarised descriptively by trial arm and the proportions compared using a logistic regression model. Proportions categorised as study period responders for stool consistency and abdominal pain were also compared using logistic regression.

Secondary outcomes were compared between trial arms using either a linear mixed effects model for repeated measures or a mixed effects logistic regression model. Unstructured variance-covariance matrices were used to allow for the anticipated correlation between repeated outcome measurements. For open-label analysis all outcomes were analysed separately for patients receiving placebo or enterogel in the double-blind phase. Where necessary, multiple imputation was used to impute missing values and conditional logistic regression applied to compare the proportions with the primary outcome in both phases. Proportions categorised as study

**Table 2** Analysis of study period responders in double-blind phase (ITT population): the table shows responder rates for composite (primary outcome) and individual stool consistency and abdominal pain

Study period responder	Placebo	Enterogel	OR (95% CI)*	P value
Primary outcome				
Observed data (excluding weeks with <4 values)	52/214 (24.3)	80/214 (37.4)	1.95 (1.28 to 2.99)	0.0020
Observed data (excluding weeks with <7 values)	37/206 (18.0)	61/204 (29.9)	2.03 (1.26 to 3.25)	0.0035
Stool consistency				
Observed data (excluding weeks with <4 values)	91/214 (42.5)	125/214 (58.4)	1.97 (1.33 to 2.92)	0.0007
Observed data (excluding weeks with <7 values)	67/206 (32.5)	99/204 (48.5)	2.02 (1.34 to 3.05)	0.0007
Abdominal pain				
Observed data (excluding weeks with <4 values)	86/214 (40.2)	114/214 (53.3)	1.80 (1.22 to 2.67)	0.0034
Observed data (excluding)	70/206 (34.0)	94/204 (46.10)	1.76 (1.16 to 2.65)	0.0074

Data are reported as number of patients, proportion (%), and OR (95% CI).

\*Adjusted for age and sex.



**Table 3** Analysis of the secondary outcomes in double-blind phase (ITT population)

Model	Placebo	Enterosgel	Treatment effect (95% CI)*	P value
Stool consistency (excluding weeks with <4 values)				
Days $\geq 1$ stool of BSFS 6/7 (week 1–8)†	3.16 (1.89)	2.46 (1.82)	-0.58 (-0.87 to -0.28)	0.0001
Days $\geq 1$ stool of BSFS 6/7 (week 1–4)†	3.33 (1.85)	2.70 (1.85)	-0.50 (-0.79 to -0.21)	0.0007
Days $\geq 1$ stool of BSFS 6/7 (week 5–8)†	2.92 (2.13)	2.08 (1.86)	-0.67 (-1.02 to -0.32)	0.0002
Abdominal pain (excluding weeks with <4 values)				
Mean score (week 1–8)	4.02 (1.85)	3.59 (1.84)	-0.35 (-0.62 to -0.09)	0.0086
Mean score (week 5–8)	3.70 (1.99)	3.10 (1.96)	-0.50 (-0.83 to -0.18)	0.0026
Stool consistency (excluding weeks with <7 values)				
Days $\geq 1$ stool of BSFS 6/7 (week 1–8)†	3.14 (1.89)	2.47 (1.83)	-0.53 (-0.82 to -0.24)	0.0004
Days $\geq 1$ stool of BSFS 6/7 (week 1–4)†	3.30 (1.87)	2.65 (1.83)	-0.50 (-0.80 to -0.21)	0.0009
Days $\geq 1$ stool of BSFS 6/7 (week 5–8)†	2.94 (2.16)	1.96 (1.89)	-0.76 (-1.13 to -0.39)	<0.0001
Abdominal pain (excluding weeks with <7 values)				
Mean score (week 1–8)	4.02 (1.85)	3.56 (1.83)	-0.36 (-0.63 to -0.10)	0.0079
Mean score (week 5–8)	3.64 (1.99)	2.93 (1.91)	-0.61 (-0.96 to -0.25)	0.0008
Stool frequency				
Mean no daily stools (week 1–4)	2.96 (2.74–3.18)	2.67 (2.45–2.89)	-0.30 (-0.60 to 0.01)	0.0554
Mean no daily stools (week 5–8)	2.81 (2.59–3.03)	2.47 (2.25–2.69)	-0.35 (-0.66 to 0.04)	0.0251
Bloating				
Mean bloating score (week 1–8)	3.14 (2.95–3.33)	2.73 (2.54–2.92)	-0.42 (-0.69 to 0.15)	0.0021
Mean bloating score (week 5–8)	3.06 (2.86–3.25)	2.50 (2.30–2.69)	-0.57 (-0.85 to 0.29)	<0.0001
Urgency				
Mean urgency score (week 1–8)	3.08 (2.89–3.27)	2.51 (2.32–2.70)	-0.59 (-0.85 to 0.33)	<0.0001
Mean urgency score (week 5–8)	2.99 (2.79–3.19)	2.29 (2.09–2.48)	-0.72 (-0.99 to 0.44)	<0.0001
Adequate relief				
Adequate relief (week 1–8)‡	0.22 (0.16–0.31)	0.56 (0.46–0.65)	4.44 (2.49 to 7.91)	<0.0001
Adequate relief (week 1–4)‡	0.16 (0.10–0.23)	0.45 (0.34–0.56)	4.40 (2.34 to 8.28)	<0.0001
Adequate relief (week 5–8)‡	0.30 (0.21–0.40)	0.69 (0.58–0.77)	5.21 (2.74 to 9.89)	<0.0001
Loperamide use				
Loperamide use (week 1–8)§	1.46 (1.21–1.71)	0.97 (0.73–1.22)	-0.51 (-0.86 to -0.15)	0.0049
Loperamide use (week 5–8)§	1.55 (1.29–1.81)	0.97 (0.72–1.23)	-0.59 (-0.95 to -0.23)	0.0014

Data are reported as mean (SD or range) and treatment effect (95% CI).


\*Adjusted for age, sex and the baseline measure of the outcome.

†Mean number of days per week with at least one stool of BSFS type 6 or 7 over.

‡Proportion of patients reporting adequate relief (95% CI).

§Mean number of days per week loperamide used.

BSFS, Bristol Stool Form Scale; ITT, intention-to-treat.



**Figure 4** Proportion of patients reporting adequate relief of their symptoms over the double-blind phase (week 1–4 and week 5–8) and open-label phase (week 9–16), for the enterosgel allocated group and placebo allocated group (mean±95% CI). #Allocated placebo in the double-blind phase.

period responders for stool consistency and abdominal pain were also compared between phases using conditional logistic regression. Other secondary outcomes were analysed using equivalent mixed effects models to those implemented in the double-blind phase. All models were adjusted for the baseline measurement of the outcome, patient age and sex. Analysis of the follow-up phase and exploratory outcomes was descriptive only. The safety population included all randomised participants who took at least one dose of the study treatment.

#### Patient involvement

Patients were involved at all stages of the trial including review of the protocol and trial materials and testing the diaries and questionnaires. A survey of 55 patients from the Chief Investigator's outpatient clinic supported the use of an electronic diary with daily text reminders, and the dosage structure. Patient feedback was instrumental in the overall design, burden of patient reporting, and subsequent virtual trial set up, it was also collected at the 2-week visit and participants were approached for an interview about their experience. On request we included an open-label phase so participants could

**Table 4** Adverse events (AEs) during the double-blind phase in the safety population; possibly, probably or definitely related to treatment

Adverse event	Placebo (n=213)	Enterosgel (n=214)
Nausea	8 (3.8%) (1 s, 2 mo, 5 m)*	8 (3.7%) (2 mo, 6 m)
Abdominal pain	4 (1.9%) (2 mo, 2 m)	3 (1.4%) (1 mo, 2 m)
Bloating	3 (1.4%) (2 mo, 1 m)	6 (2.8%) (3 mo, 3 m)
Constipation	2 (0.9%) (1 s, 1 m)	2 (0.9%) (1 s, 1 m)
Headache	2 (0.9%) (2 m)	2 (0.9%) (1 s, 1 m)
Dry mouth	2 (0.9%) (1 mo, 1 m)	1 (0.5%) (1 m)
Backpain	0 (0%)	2 (0.9%) (1 s, 1 mo)
Loss of appetite	0 (0%)	2 (0.9%) (2 m)

AE listed in descending order of frequency in the placebo group. The AEs listed were reported in two or more cases in either treatment group.  
\*AE severity; s=severe, mo=moderate, m=mild.

try treatment. We also disseminated the trial results to participants via an interactive webinar.

## RESULTS

### Study participants

Overall, 617 patients were screened and 440 (71.3%) were randomised (122 at general practitioner and 140 at hospital sites and 170 via virtual site) 1:1 to receive either enterosgel (n=219) or placebo (n=221). In total, 393 (89.3%) participants completed the double-blind phase and were enrolled in the open-label phase, of whom 349 (88.8%) completed the open-label phase, and 265 (75.9%) entered the follow-up phase (figure 3). Primary outcome data were available for 215 participants in the placebo arm and 216 in the enterosgel arm. One patient from the enterosgel arm was excluded from analyses as their screening phase diary data were unusable. Thus, 431 patients were included in the ITT population for the primary endpoint analysis. Two patients in each arm did not take at least one dose of study treatment and were excluded from the safety population (n=427).

Demographics and baseline characteristics of randomised patients in the ITT population were similar between the treatment groups at baseline (table 1). Diary completion and adherence to study treatment were high in both the double-blind and open-label phases and were comparable between treatment groups. Median number of treatment doses taken was two doses in both arms and phases (online supplemental files S1 and S2).

### Primary outcome

Following 8 weeks of double-blind treatment, in the ITT population, the percentage of treatment responders was higher in the enterosgel group than the placebo group (table 2). Excluding weeks with data for <4 days, 37.4% of patients in the enterosgel group and 24.3% in the placebo group were classified as responders (Number needed to treat (NNT):8; OR 1.95 (95% CI 1.28 to 2.99, p=0.0020)). Similar results were seen when excluding weeks with data for <7 days, in the multiple imputation analyses, and in the PP population (online supplemental files S3 and S4), indicating that missing data had little impact on results.

### Secondary outcomes for double-blind phase

Table 2 shows categorical response rates for stool consistency were higher for the enterosgel than placebo group (58.4% vs 42.5%, NNT 6, OR 1.97). Mean number of days per week with at least one stool of BSFS type 6 or 7 was reduced by the

intervention (2.46 vs 3.16 days) (table 3). The treatment effect for the latter endpoint was larger in magnitude in weeks 4–8 of the 8-week double-blind phase (-0.67 vs -0.50). Similarly, analysis of abdominal pain showed higher response rates in the enterosgel than placebo group (53.3 vs 40.2%, NNT 8, OR 1.80); this was also manifest as lower mean abdominal pain scores (3.59 vs 4.02). The treatment effect for pain score was also larger in magnitude in the later 4 weeks compared with the overall 8 weeks (-0.50 vs -0.35). Similar to the primary outcome, results were consistent when analysed using multiple imputation (online supplemental files S3 and S5).

Statistically significant differences were also found for the other diary-based outcomes of stool frequency, bloating, urgency, and loperamide use, all indicating more improvement in the enterosgel group compared with the placebo group (table 3). Questionnaire data over the 8 weeks showed significant differences for the IBS-SSS questionnaire score (207.29 vs 255.17, treatment effect -37.27, p=0.0002) and the IBS-QOL questionnaire score (60.88 vs 55.24, treatment effect 5.01, p=0.0024), indicating greater improvement in the enterosgel group compared with the placebo, that was also higher for week 5–8, than weeks 1–4 (online supplemental file S6). There was no statistically significant difference in the WPA:IBS questionnaire for work time missed due to IBS symptoms, low statistical significance for impairment while working and overall work impairment, however, activity impairment was significant (p=0.0005), in favour of enterosgel.

### Adequate relief of symptoms

The proportion of patients reporting adequate relief over 8 weeks was greater in the enterosgel compared with placebo group (0.56 vs 0.22). Figure 4 shows adequate relief was higher in the enterosgel group for week 5–8 of the double-blind phase (0.69 vs 0.45) and continued to improve further for both groups in the open-label phase (weeks 9–16).

### Open-label and follow-up phase outcomes

Following 8 weeks of open-label treatment, 349 patients completed the open-label phase. Comparison with secondary outcome data reported during the double-blind phase confirmed continued treatment effect for the same observed variables (online supplemental files S7–S10). Mean days per week loperamide use fell in the Enterosgel group in contrast to the placebo (week 1: 0.83 vs 1.14, week 8: 0.77 vs 1.47) and continued to fall during open label (week 16: 0.68 vs 0.87), suggesting patients experienced a continued improvement in symptoms.

At the completion of the open-label phase 264 (75.9%) (week 16, figure 2) of patients reported adequate relief of symptoms over the previous 4 weeks and continued into the follow-up phase, representing 60% of all patients that began the trial. 253 patients completed the follow-up phase of whom 186 (74.1%) reported an increased or maintained treatment benefit, with 203 (80.6%) reporting they chose to continue treatment with enterosgel (using left-over supplies from the open-label phase or purchased OTC product). Most patients that continued treatment reported using it on most days (106 (52.2%)) and 133 (53.2%) said they used less loperamide than before the trial (online supplemental file 11).

### Safety data

Similar proportions of patients reported at least one AE during the double-blind phase in the placebo group compared with the enterosgel group (24.4% vs 21.0%). AEs considered by the

investigators as possibly, probably or definitely related to treatment were reported by 8.9% in the Placebo group and 7.0% in the enterosgel group (table 4). Total number of AEs was similar (33 enterosgel vs 32 placebo) and there were no clear differences in event terms between the groups. All other AEs, and those reported during the open-label phase, are listed in the online supplemental file 12. There were six serious adverse events reported in five patients, but none were considered related to enterosgel.

## DISCUSSION

Despite IBS-D being common and causing much suffering, treatments for this condition are limited, and patient satisfaction with treatment is low.<sup>26</sup> The current trial is the largest to date investigating the efficacy and safety of enterosgel in the treatment of patients with IBS-D and represents the first multicentre, double-blind RCT. In accordance with Food and Drug Administration (FDA) guidance,<sup>14</sup> efficacy was evaluated over an 8-week treatment period. We included further 8-week open-label and follow-up phases to match treatment duration to other IBS-D trials,<sup>27</sup> evaluate any cumulative treatment benefit and for safety assessment.

The study showed that enterosgel significantly improved the composite primary endpoint of abdominal pain and stool consistency, compared with placebo. Analysis was conducted on both observed data and using multiple imputation, though there were no distinguishing differences in outcomes. Treatment effect was lower for abdominal pain alone than for the composite endpoint, or for stool consistency alone, consistent with the hypothesised mode of action in IBS-D, which is the binding and removal of diarrhoea-inducing molecules from the gut. At baseline the mean number of days per week with loose stool was 4.4 days, which fell to 2.1 days for weeks 5–8 in the enterosgel group, that is, more than 50% reduction.

As with many IBS trials,<sup>28</sup> we observed a significant placebo effect (18%–24.5%) in the observed data, although this was comparable to a recent meta-analysis (16.2%) for the same composite endpoint<sup>29</sup> and matched the 20% rate used to estimate sample size.

Significant improvement with enterosgel treatment was also seen in the outcomes of stool frequency, bloating and urgency, compared with the placebo group, as well as in the IBS symptoms, QOL and activity measurements recorded in the IBS-SSS and IBS-QOL questionnaires. The WPA:IBS showed less effect, apart for activity impairment, the COVID-19 pandemic which occurred during ~50% of the trial and working from home may have impacted results. These individual outcomes support the composite primary outcome and suggest that, unlike loperamide, the array of IBS-D symptoms can benefit from this treatment. In the open-label phase, primary and secondary endpoints confirmed that treatment effect was improved further in the treatment allocated arm, and that in the placebo allocated arm significant improvement in endpoints followed the expected response. Being un-blinded, these improvements could represent physiological treatment responses, or represent the power of belief in treatment has on outcome.

The composite primary outcome measure was developed in response to historically high placebo response rates in IBS trials<sup>30</sup> and sets a high threshold. Although this measure succeeds in lowering placebo response, it does not reflect overall patient satisfaction.<sup>29 31</sup> Adequate relief is a binary measure, shown to correlate with multiple endpoints<sup>32</sup> and can provide a valid secondary outcome to support efficacy of IBS therapies.<sup>33</sup> We

showed that proportion of adequate relief was considerably higher in the treatment arm in the double-blind phase (0.56) and open-label phase (0.66 and 0.72), than the composite responder rate suggested (37.4%). Adequate relief analysis over the three phases showed there was a progressive benefit over time and suggests that other symptoms such as urgency have a greater impact on QOL. During the follow-up phase, a significant proportion of patients (80.9%) chose to continue with OTC enterosgel after the trial treatment had ended, indicating patients' overall satisfaction and tolerance of the treatment.

Enterosgel exhibited a favourable safety profile, demonstrated by a low percentage of patients with adverse events. This is not surprising as there are over 10 years postmarket surveillance for this treatment in Europe, where it is used in young children and pregnancy, with no adverse event signals.

## Limitations

Since eligibility was assessed according to the current Rome IV criteria, the applicability of our findings to the estimated 50% of patients with IBS not matching the Rome IV criteria,<sup>34</sup> including those with milder pain, is not known. We may, however, have mitigated for these patients by recruiting a proportion of cases directly from the community setting and when we reduced the eligibility abdominal pain score at screening to lower screening failures.

Medical device studies commonly lack a placebo arm, although we used a placebo arm, we recognised that even when using the diluted treatment, it was not possible to exactly replicate with an identical placebo. We mitigated for this by excluding any patients with previous enterosgel use, who might recognise a difference, however, it is possible that there has been some un-blinding for patients initially on placebo once they entered the open label phase. We failed to ask patients if they were on treatment or placebo to assess the degree of unblinding.

This was a pragmatic study with flexible treatment instructions in an incremental dosing pattern, to allow participants to find the most appropriate dose to treat their symptoms. Such flexibility hindered our ability to find a set dosage scheme for maximal treatment benefit and as median treatment dose was only two doses per day across the study, this may have prevented patients from taking sufficient treatment to be classified as a responder. At the outset we recognised that this may be a limitation, but we wanted to provide as 'real world' a scenario as possible where patient treatment adherence varies, and IBS symptoms fluctuate over time.

Our primary outcome analysis used multiple imputation for missing diary entries for both stool consistency and abdominal pain. Although this method has been widely adopted to handle missing data<sup>35</sup> it can introduce bias, but it is reassuring that the resulting ORs were comparable to the observed data.

Although we followed FDA guidance with an 8week blinded phase, several recently published IBS-D trials have 12-week treatment durations,<sup>36 37</sup> which could limit comparisons.

## CONCLUSION

The results from this study show that enterosgel is safe and effective for treatment of the main IBS-D symptoms, especially urgency which is so incapacitating. Although the primary action is on stool consistency, it provides benefit to global symptoms and improvement in QOL and potentially provides a valid alternative to the few treatment options currently available for patients with this condition.



**Author affiliations**<sup>1</sup>Research, Enteromed Ltd, London, UK<sup>2</sup>Clever Cookie Ltd, Hove, UK<sup>3</sup>Faculty of Health, Peninsula Medical School, Plymouth, UK<sup>4</sup>Department of Medical Statistics, School of Hygiene and Tropical Medicine, London, UK<sup>5</sup>Queen Mary University Faculty of Medicine and Dentistry, Blizard Institute, London, UK<sup>6</sup>Division of Diabetes, Endocrinology and Gastroenterology, The University of Manchester, Manchester, UK<sup>7</sup>Gastroenterology, Northern Care Alliance NHS Foundation Trust, Salford, UK<sup>8</sup>The Village Practice, Thornton-Cleveleys, UK<sup>9</sup>Neurogastroenterology Unit, Wythenshawe Hospital, Manchester, UK<sup>10</sup>Department of Gastroenterology, County Durham and Darlington NHS Foundation Trust, Darlington, UK<sup>11</sup>School of Health and Life Sciences, University of Teesside, Middlesbrough, UK

**Acknowledgements** Thank you to the legal manufacturer Bioline Products s.r.o for funding this study. A special thank you to our chief investigator Prof Yan Yiannakou's team at the NIHR PRC Newcastle who set up and ran the virtual site. Thank you to Dr John Gregson from the London School of Hygiene and Tropical Medicine for his validation of the statistical analysis. Thank you to Dr Maria Eugenicos from the University of Edinburgh for her contribution in chairing the DMC. We would also like to acknowledge and thank all the principal investigators and research nurses who have assisted in recruitment, including, Prof Yan Yiannakou, University Hospital of North Durham; Dr Peter Isaacs, Dr Shelly Soo, Blackpool Victoria Hospital; Dr Preeti Pandya, The Village Practice; Dr Vanessa Short, Newton Place Surgery NHS General Practice; Dr David Graham, Queens Road Surgery; Dr Stephen Doherty, Well Close Medical Group; Dr Siobhan Macintyre, Dr Abigail Gallagher, Bodey Medical Centre; Dr Sam Davies, West Walk Surgery; Dr David Lewis, Vauxhall Primary Health Care; Dr Anurag Agrawal, Doncaster Hospital; Dr Mark Blagden, Dr Adrian Beltran-Martinez, Ashgate Medical Practice; Dr Priya Ganeshkumar, Pound Hill Medical Group; Dr Anthony Hobson, The Functional Gut Clinic; Prof Ramesh Arasaradnam, University Hospitals of Coventry and Warwickshire; Dr Justine Norman, Redburn Park Medical Centre; Dr Swaminathan Thiagarajan, Pickering Medical Practice; Dr Steve Lewis, University Plymouth Hospitals NHS Trust; Dr Adam Farmer, Royal Stoke University Hospital; Dr Farzan Kamali, Branch End Surgery; Dr Mary Philipsz, Castlegate and Derwent Surgery; Dr Timi Patani, Warrington Hospital; Prof Ahmet Fuat, Carmel Medical Practice; Dr Zahid Mahmood, Stepping Hill Hospital; Dr Safa Al-Shamma, The Royal Bournemouth Hospital; Dr Jamal Hayat, St Georges Hospital; Dr Sukhdev Chatu, King's College Hospital NHS Foundation Trust; Prof Peter Whorwell, Manchester NHS Foundation Trust.

**Contributors** CAH and AK: study concept and design, analysis and interpretation of data, administrative and material support and study supervision. EM: study concept and design, arranging funding, administrative and material support and overall study supervision. PP, PW: principal investigator, study design, study supervision and recruitment. CHK: study design, study supervision, analysis and interpretation of data and technical support. JM: study design, study supervision, analysis and technical support. MD, VA: statistical analysis and interpretation of data. YY: chief investigator, guarantor, study concept and design, interpretation of data, study supervision, recruitment. All authors had access to the study data and reviewed and approved the final manuscript. CAH and YY contributed equally to writing this manuscript.

**Funding** The study was funded by Bioline Products s.r.o, the legal manufacturer of the medical device Enterogel in the EU.

**Competing interests** EM is CEO of Enteromed the study Sponsor, and exclusive distributor of Enterogel in the UK. CAH is employed by Enteromed. YY was the chief investigator and was recompensed with CI fees paid to his institution. PW, JM, PP, CHK were members of the trial steering committee and were given a small honorarium for their time. AK was subcontracted by the sponsor as the study manager. VA, MD, JG were subcontracted by the sponsor to conduct the analysis.

**Patient and public involvement** Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by Name of Ethics Committee: North East-Tyne & Wear South Research Ethics Committee Reference number: REC reference: 18/NE/0023. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those

of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

**ORCID iD**Carol Angela Howell <http://orcid.org/0000-0001-5713-6177>**REFERENCES**

- Vasant DH, Paine PA, Black CJ, *et al*. British Society of gastroenterology guidelines on the management of irritable bowel syndrome. *Gut* 2021;70:1214–40.
- Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA* 2015;313:949–58.
- Longstreth GF, Thompson WG, Chey WD, *et al*. Functional bowel disorders. *Gastroenterology* 2006;130:1480–91.
- Hellström PM, Saito YA, Bytzer P, *et al*. Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. *Am J Gastroenterol* 2011;106:1299–307.
- Weinland SR, Morris CB, Hu Y, *et al*. Characterization of episodes of irritable bowel syndrome using ecological momentary assessment. *Am J Gastroenterol* 2011;106:1813–20.
- Su AM, Shih W, Presson AP, *et al*. Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. *Neurogastroenterol Motil* 2014;26:36–45.
- The International Foundation for Functional Gastrointestinal Disorders. *Ibs in the real world survey. summary findings*, 2002. <https://www.iffgd.org/images/pdfs/IBSRealWorld.pdf>
- Ibs global impact report, 2018. Available: <https://badgut.org/wp-content/uploads/IBS-Global-Impact-Report.pdf> [Accessed 01 Nov 2021].
- Chang F-Y, Lu C-L, Chen C-Y, *et al*. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. *J Gastroenterol Hepatol* 2007;22:2266–72.
- Tack JF, Miner PB, Fischer L, *et al*. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2011;34:868–77.
- Howell CA, Mikhailovsky SV, Markaryan EN, *et al*. Investigation of the adsorption capacity of the enterosorbent Enterogel for a range of bacterial toxins, bile acids and pharmaceutical drugs. *Sci Rep* 2019;9:5629.
- Howell CA, Markaryan E, Allgar V, *et al*. Enterogel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial. *BMJ Open Gastroenterol* 2019;6:e000287.
- Kemppinen A, Howell C, Allgar V, *et al*. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterogel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. *Trials* 2020;21:122.
- US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry. Irritable bowel syndrome - clinical evaluation of drugs for treatment, 2012. Available: <https://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf> [Accessed 01 Nov 2021].
- Mearin F, Lacy BE, Chang L. Bowel disorders. *Gastroenterology* 2016;S0016-5085:00222-5.
- Stannard C, ed. *Opioids for persistent pain: Information for patients*. The British Pain Society, 2010.
- Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. *Aliment Pharmacol Ther* 1997;11:395–402.
- Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmacoeconomics* 1993;4:353–65.
- Reilly MC, Bracco A, Ricci J-F, *et al*. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire-irritable bowel syndrome version (WPAI:IBS). *Aliment Pharmacol Ther* 2004;20:459–67.
- Patrick DL, Drossman DA, Frederick IO, *et al*. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. *Dig Dis Sci* 1998;43:400–11.
- Drossman DA, Patrick DL, Whitehead WE, *et al*. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. *Am J Gastroenterol* 2000;95:999–1007.
- Spiller RC, Humes DJ, Campbell E, *et al*. The patient health questionnaire 12 somatic symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. *Aliment Pharmacol Ther* 2010;32:811–20.



- 23 European Medicines Agency. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. 25 September 2014. CPMP/EWP/785/97 Rev. 1, 2014. Available: [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-revision-1\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-revision-1_en.pdf) [Accessed 01 Nov 2021].
- 24 Garsed K, Chernova J, Hastings M, *et al.* A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. *Gut* 2014;63:1617–25.
- 25 Lacy BE, Chey WD, Cash BD, *et al.* Eluxadolone efficacy in IBS-D patients who report prior loperamide use. *Am J Gastroenterol* 2017;112:924–32.
- 26 Rangan V, Ballou S, Shin A, *et al.* Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America survey. *Gastroenterology* 2020;158:786–8.
- 27 Black CJ, Burr NE, Camilleri M, *et al.* Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. *Gut* 2020;69:74–82.
- 28 Shah E, Pimentel M. Placebo effect in clinical trial design for irritable bowel syndrome. *J Neurogastroenterol Motil* 2014;20:163–70.
- 29 Barberio B, Savarino EV, Black CJ, *et al.* Placebo response rates in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: meta-analysis. *Clin Gastroenterol Hepatol* 2022;20:e923–44.
- 30 Lacy BE, Lembo AJ, Macdougall JE, *et al.* Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C. *Neurogastroenterol Motil* 2014;26:326–33.
- 31 Chey WD, Dove LS, Andrae DA, *et al.* Early response predicts a sustained response to eluxadolone in patients with irritable bowel syndrome with diarrhoea in two phase 3 studies. *Aliment Pharmacol Ther* 2017;45:1319–28.
- 32 Mangel AW, Hahn BA, Heath AT, *et al.* Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. *J Int Med Res* 1998;26:76–81.
- 33 Drossman DA, Chang L, Chey W, *et al.*, eds. *Rome IV: Functional gastrointestinal disorders*. Fourth ed. Raleigh, NC: Rome foundation, 2016.
- 34 Sperber AD, Bangdiwala SI, Drossman DA, *et al.* Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. *Gastroenterology* 2021;160:99–114.
- 35 Jakobsen JC, Gluud C, Wetterslev J, *et al.* When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. *BMC Med Res Methodol* 2017;17:162.
- 36 Dove LS, Lembo A, Randall CW, *et al.* Eluxadolone benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. *Gastroenterology* 2013;145:329–38.
- 37 Chang L, Ameen VZ, Dukes GE, *et al.* A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. *Am J Gastroenterol* 2005;100:115–23.

**Supplementary data.****METHODS****Participants**

To be eligible for randomisation, patients were required to have completed the daily diary on at least 11 of 14 days ( $\geq 75\%$ ) during the screening period. Exclusion criteria were loose stools (BSFS 6 or 7) on less than 3 days during screening period, and average abdominal pain  $< 2.5$  during the 14-day screening period. This was amended from an initial average abdominal pain score of  $< 3$ , in response to the relatively high numbers of patients failing this criterion.

**Trial management**

A trial management group was set up to manage the trial from design to implementation. The group held regular meetings to monitor trial progress and to decide on any other management issues. A trial steering committee (TSC) was also set up to provide scientific advice during protocol development and throughout the trial. An Independent Data Monitoring Committee held two meetings during the trial to review blinded safety and efficacy data.

**Multiple imputation**

The number of weeks requiring at least one missing value of abdominal pain or stool consistency to be imputed were;

- Placebo = 462/1,720 (26.9%)
- Enterosgel = 489/1,728 (28.3%)

For weeks that required at least one missing value of abdominal pain or stool consistency to be imputed, the average number of missing values was:

- Placebo (median and interquartile range) = 4 (2 to 6)
- Enterosgel (median and interquartile range) = 6 (4 to 8)

The maximum permissible number of missing values within a week was 14 (7 for abdominal pain and 7 for stool consistency).

**Table S1.** Diary completion and adherence to study treatment during double-blind phase

	<b>Placebo (n=221)</b>		<b>Enterosgel (n=219)</b>	
Number of days patient diary was completed	55	(47 to 56)	54	(48 to 56)
Number of days study treatment was used	50	(42 to 53)	49	(41 to 52)
Number of days that doses of study treatment were used, n (%)				
0 doses	283	(2.8)	546	(5.5)
1 dose	1137	(11.3)	1849	(18.5)
2 doses	3972	(39.5)	4535	(45.4)
3 doses	1487	(14.8)	1016	(10.2)
4 doses	2535	(25.2)	1616	(16.2)
5 doses	90	(0.9)	94	(0.9)
6 doses	543	(5.4)	338	(3.4)
7+ doses	13	(0.1)	6	(0.1)

Data are reported as Median (IQR) and range, out of 56-day double-blind phase

**Table S2.** Diary completion and adherence to study treatment during open-label phase

	<b>Placebo (n=221)</b>		<b>Enterosgel (n=219)</b>	
Number of days patient diary was completed	52	(39 to 56)	51	(40 to 56)
Number of days study treatment was used	49	(32 to 53)	47	(33 to 53)
Number of days that doses of study treatment were used, n (%)				
0 doses	406	(4.5)	470	(5.3)
1 dose	1755	(19.3)	1978	(22.2)
2 doses	4231	(46.4)	3900	(43.8)
3 doses	1078	(11.8)	819	(9.2)
4 doses	1136	(12.5)	1356	(15.2)
5 doses	61	(0.7)	139	(1.6)
6 doses	418	(4.6)	244	(2.7)
7+ doses	28	(0.3)	6	(0.1)

Data are reported as Median (IQR) and range, out of 56-day double-blind phase

**Table S3.** Analysis of study period responders in double-blind phase (ITT population) by multiple imputation: the table shows responder rates for composite (primary outcome) and individual stool consistency and abdominal pain.

Study period responder	Placebo	Enterogel	Odds ratio (95%CI)*	p value
Primary outcome	n=215	n=216	1.89 (1.21-2.97)	0.0054
Primary outcome (excluding Weeks with <4 values)	n=214	n=214	1.94 (1.25-3.00)	0.0030
<b>Stool consistency</b>				
All weeks	n=215	n=216	2.0 (1.31 to 3.06)	0.0014
Excluding Weeks with <4 values	n = 214	n = 214	1.93 (1.30 to 2.85)	0.0011
<b>Abdominal pain</b>				
All weeks	n=215	n=216	1.62 (1.08 to 2.45)	0.0207
Excluding Weeks with <7 values	n = 214	n = 214	1.72 (1.16 to 2.56)	0.0074

Data are reported as number of patients, and odds ratio (range)

\*Adjusted for age and sex

**Table S4.** Analysis of the primary outcome in double-blind phase (PP population)

Study period responder	Placebo	Enterogel	Odds ratio (95%CI)*	p value
Observed data (excluding Weeks with <4 values)	52/212 (24.5)	80/208 (38.5)	2.02 (1.32 to 3.10)	0.00129
Observed data (excluding Weeks with <7 values)	37/206 (18.0)	61/199 (30.7)	2.11 (1.31 to 3.39)	0.00216
Multiple imputation	n=212	n=208	1.96 (1.25 to 3.07)	0.00340
Multiple imputation (excluding Weeks with <4 values)	n=212	n=208	2.00 (1.29 to 3.10)	0.00198

Data are reported as number of patients, proportion (%), and odds ratio (range)

\*Adjusted for age and sex



**Table S5.** Analysis of the stool consistency and abdominal pain in double-blind phase (ITT population) by multiple imputation

Model	Placebo	Enterosgel	Treatment effect (95%CI)*	p value
<b>Stool consistency</b>				
Days ≥ 1 stool of BSFS 6/7 (week 1-4)#	n=215	n=216	-0.52 (-0.79 to -0.25)	0.0002
Days ≥ 1 stool of BSFS 6/7 (week 5-8)‡	n=215	n=216	-0.68 (-1.00 to -0.36)	<0.0001
<b>Abdominal pain</b>				
Mean score (week 1-8)	n=215	n=216	-0.38 (-0.63 to -0.13)	0.0027
Mean score (week 5-8)	n=215	n=216	-0.51 (-0.81 to -0.20)	0.0011
<b>Stool consistency (excluding weeks with &lt;4 values)</b>				
Days ≥ 1 stool of BSFS 6/7 (week 1-4)#	n = 214	n = 214	-0.50 (-0.79 to -0.21)	0.00079
Days ≥ 1 stool of BSFS 6/7 (week 5-8)‡	n = 198	n = 198	-0.67 (-1.01 to -0.33)	0.00014
<b>Abdominal pain (excluding weeks with &lt;4 values)</b>				
Mean score (week 1-8)	n = 214	n = 214	-0.35 (-0.62 to -0.09)	0.00835
Mean score (week 5-8)	n = 198	n = 198	-0.49 (-0.82 to -0.17)	0.00314

Data are reported as mean (SD) and treatment effect (mean days, mean pain score)

\* Adjusted for age, sex, and the baseline measure of the outcome

‡ Mean number of days per week with at least one stool of BSFS type 6 or 7 over

**Table S6.** Analysis of the secondary questionnaire outcomes in double-blind phase (ITT population)

Model	Placebo	Enterosgel	Treatment effect (95%CI)*	p value
<b>IBS-SSS</b>				
Total score over 8 weeks	255.17 (239.60 to 270.74)	207.29 (191.64 to 222.94)	-37.27 (-57.08 to -17.46)	0.00023
Total score during weeks 1-4	270.26 (254.27 to 286.24)	231.40 (215.33 to 247.47)	-28.63 (-49.09 to -8.17)	0.00610
Total score during weeks 5-8	240.84 (224.90 to 256.78)	184.49 (168.47 to 200.51)	-45.69 (-66.08 to -25.30)	0.00001
<b>IBS-QoL</b>				
Total score over 8 weeks	55.24 (52.02 to 58.47)	60.88 (57.64 to 64.12)	5.01 (1.78 to 8.24)	0.00238
Total score during weeks 1-4	52.14 (48.72 to 55.56)	56.41 (52.95 to 59.86)	3.60 (-0.03 to 7.22)	0.05162
Total score during weeks 5-8	57.67 (54.33 to 61.02)	64.00 (60.65 to 67.35)	5.77 (2.30 to 9.23)	0.00110
<b>PHQ-12 SS</b>				

Mean total score over 8 weeks	6.68 (6.16 to 7.20)	6.54 (6.02 to 7.07)	-0.19 (-0.74 to 0.37)	0.51295
Mean total score at week 4	7.19 (6.62 to 7.76)	7.18 (6.60 to 7.75)	-0.08 (-0.72 to 0.56)	0.80618
Mean total score at week 8	6.28 (5.73 to 6.83)	6.11 (5.56 to 6.66)	-0.21 (-0.82 to 0.39)	0.48872
Mean headache score over 8 weeks	0.72 (0.63 to 0.81)	0.75 (0.66 to 0.84)	0.01 (-0.09 to 0.12)	0.79332
Mean headache score at week 4	0.79 (0.68 to 0.89)	0.80 (0.69 to 0.91)	0.00 (-0.13 to 0.13)	0.97179
Mean headache score at week 8	0.67 (0.57 to 0.76)	0.71 (0.61 to 0.81)	0.03 (-0.09 to 0.15)	0.62198
Mean tiredness score over 8 weeks	1.28 (1.19 to 1.37)	1.28 (1.19 to 1.37)	-0.01 (-0.12 to 0.10)	0.83306
Mean tiredness score at week 4	1.37 (1.27 to 1.47)	1.44 (1.34 to 1.55)	0.05 (-0.08 to 0.18)	0.46297
Mean tiredness score at week 8	1.20 (1.10 to 1.30)	1.16 (1.06 to 1.26)	-0.05 (-0.17 to 0.07)	0.43875
Mean sleep score over 8 weeks	1.10 (1.00 to 1.20)	1.07 (0.97 to 1.17)	-0.06 (-0.18 to 0.06)	0.31410
Mean sleep score at week 4	1.20 (1.08 to 1.31)	1.16 (1.05 to 1.28)	-0.06 (-0.21 to 0.08)	0.39173
Mean sleep score at week 8	1.02 (0.91 to 1.13)	1.00 (0.89 to 1.11)	-0.05 (-0.19 to 0.08)	0.44957
<b>WPA:IBS</b>				
Mean % of work time missed due to IBS symptoms over 8 weeks	3.82 (2.02 to 5.61)	2.86 (1.01 to 4.71)	-1.50 (-3.90 to 0.90)	0.22123
Mean % impairment while working due to IBS symptoms over 8 weeks	35.66 (31.78 to 39.54)	29.98 (25.99 to 33.97)	-5.51 (-10.72 to -0.30)	0.03813
Mean % overall work impairment due to IBS over 8 weeks	36.72 (32.74 to 40.70)	30.97 (26.88 to 35.07)	-5.38 (-10.69 to -0.06)	0.04752
Mean % activity impairment due to IBS symptoms over 8 weeks	41.30 (37.75 to 44.84)	34.80 (31.25 to 38.35)	-7.42 (-11.61 to -3.24)	0.00051

Data are reported as Mean (SD) or treatment effect (range)

\* Adjusted for age, sex, and (for continuous outcomes) the baseline measure of the outcome

‡ Proportion of patients reporting adequate relief (range)

^ Mean number of days per week loperamide used

**Table S7.** Analysis of study period responders in open-label phase (ITT population): the table shows responder rates for composite (primary outcome) and individual stool consistency and abdominal pain.

Study period responder	Open-label phase	Odds ratio (95%CI)*	p value
<b>Randomised to placebo</b>			
Primary outcome observed data (excluding Weeks with <7 values)	68/175 (38.9)	4.56 (2.21-9.37)	<0.0001
Stool consistency observed data (excluding weeks with <7 values)	94/175 (53.7)	3.80 (1.89 to 7.63)	0.0002
Abdominal pain observed data (excluding weeks with <7 values)	87/175 (49.7)	2.38 (1.25 to 4.56)	0.0085
<b>Randomised to Enterosgel</b>			
Primary outcome observed data (excluding Weeks with <7 values)	72/173 (41.6)	2.00 (1.03-3.89)	0.0413
Stool consistency observed data (excluding weeks with <7 values)	88/173 (50.9)	0.68 (0.35 to 1.31)	0.25271
Abdominal pain observed data (excluding weeks with <7 values)	98/173 (56.6)	1.35 (0.72 to 2.53)	0.34462

Data are reported as number of patients, proportion (%), and odds ratio (range)

\*Odds ratio for the open-label phase versus the double-blind phase

**Table S8.** Analysis of the stool consistency and abdominal pain in open label phase (ITT population) by multiple imputation

Model	Placebo	Odds Ratio (95%CI)*	p value	Enterosgel	Odds Ratio (95%CI)*	p value
<b>Stool consistency</b>						
Study period responder	n = 196	9.18 (3.81 to 22.13)	<0.00001	n = 188	2.04 (1.04 to 4.00)	0.03786
<b>Abdominal pain</b>						
Study period responder	n=196	7.40 (2.92 to 18.76)	0.00003	n = 188	4.34 (2.07 to 9.13)	0.00012

Data are reported as number of patients, and odds ratio (range)

\* Effect for the open-label phase versus the double-blind phase;

**Table S9.** Analysis of the secondary outcomes in open label phase

Model	Placebo allocation	Time effect (95%CI)*	p value	Enterosgel allocation	Time effect (95%CI)*	p value
<b>Stool consistency</b>						
Days $\geq$ 1 stool of BSFS 6/7 (week 1-8)†	1.85 (1.63 to 2.07)	-1.04 (-1.14 to -0.93)	<0.00001	1.78 (1.57 to 1.99)	-0.42 (-0.52 to -0.32)	<0.00001
<b>Abdominal pain</b>						
Mean score (week 1-8)	3.17 (2.92 to 3.41)	-0.86 (-0.91 to -0.81)	<0.00001	2.84 (2.59 to 3.08)	-0.76 (-0.81 to -0.71)	<0.00001
<b>Stool frequency</b>						
Mean number daily stools (week 1-8)	2.48 (2.26 to 2.70)	-0.41 (-0.46 to -0.37)	<0.00001	2.34 (2.16 to 2.52)	-0.24 (-0.28 to -0.20)	<0.00001
<b>Bloating</b>						
Mean bloating score (week 1-8)	2.50 (2.30 to 2.69)	-0.65 (-0.73 to -0.56)	<0.00001	2.31 (2.12 to 2.50)	-0.42 (-0.51 to -0.34)	<0.00001
<b>Urgency</b>						
Mean urgency score (week 1-8)	2.29 (2.10 to 2.47)	-0.81 (-0.89 to -0.72)	<0.00001	2.18 (2.00 to 2.37)	-0.33 (-0.41 to -0.24)	<0.00001
<b>Adequate relief</b>						
Proportion (week 1-8) #	0.66 (0.57 to 0.73)	5.43 (4.35 to 6.78)	<0.00001	0.72 (0.64 to 0.79)	2.11 (1.70 to 2.63)	<0.00001
<b>Loperamide use</b>						
Mean number of days (week 1-8)^	1.11 (0.84 to 1.37)	-0.35 (-0.44 to -0.27)	<0.00001	0.91 (0.70 to 1.13)	-0.06 (-0.14 to 0.02)	0.1204

Data are reported as Mean (range) and time effect (95% CI)

\* Effect for the open-label phase versus the double-blind phase separated into treatment allocation in double-blind phase, adjusted for age, sex, and (where possible, for continuous outcomes) the baseline measure of the outcome

† Mean number of days per week with at least one stool of BSFS type 6 or 7 over

# Proportion of patients reporting adequate relief (range)

^ Mean number of days per week loperamide used



**Table S10.** Analysis of the secondary questionnaire outcomes in open-label phase (ITT population)

Model	Placebo allocation	Time effect (95%CI)*	p value	Enterosgel allocation	Time effect (95%CI)*	p value
<b>IBS-SSS</b>						
Total score over 8 weeks	186.65 (171.00 to 202.30)	-67.38 (-73.62 to -61.14)	<0.00001	164.71 (149.78 to 179.65)	-43.82 (-49.76 to -37.87)	<0.00001
<b>IBS-QoL</b>						
Total score over 8 weeks	65.06 (61.93 to 68.19)	9.68 (7.99 to 11.37)	<0.00001	68.69 (65.41 to 71.97)	7.69 (5.94 to 9.45)	<0.00001
<b>PHQ-12 SS</b>						
Mean total score over 8 weeks	5.94 (5.41 to 6.47)	-0.74 (-1.07 to -0.40)	0.00002	5.79 (5.25 to 6.33)	-0.76 (-1.07 to -0.46)	<0.00001
Mean headache score over 8 weeks	0.67 (0.58 to 0.76)	-0.05 (-0.13 to 0.03)	0.19111	0.69 (0.59 to 0.78)	-0.06 (-0.13 to 0.01)	0.09232
Mean tiredness score over 8 weeks	1.11 (1.02 to 1.20)	-0.17 (-0.25 to -0.10)	0.00001	1.23 (1.13 to 1.32)	-0.05 (-0.13 to 0.02)	0.17102
Mean sleep score over 8 weeks	0.99 (0.89 to 1.09)	-0.11 (-0.19 to -0.03)	0.00783	1.05 (0.94 to 1.15)	-0.02 (-0.09 to 0.06)	0.65376
<b>WPA:IBS</b>						
Mean % of work time missed due to IBS symptoms over 8 weeks	2.87 (1.09 to 4.65)	-0.94 (-1.88 to -0.00)	0.04885	1.54 (0.26 to 2.82)	-1.54 (-2.56 to -0.52)	0.00306
Mean % impairment while working due to IBS symptoms over 8 weeks	27.57 (23.77 to 31.37)	-8.51 (-10.19 to -6.82)	<0.00001	23.57 (19.79 to 27.35)	-6.95 (-8.58 to -5.32)	<0.00001
Mean % overall work impairment due to IBS over 8 weeks	28.32 (24.44 to 32.20)	-8.79 (-10.52 to -7.06)	<0.00001	24.13 (20.26 to 28.00)	-7.53 (-9.25 to -5.82)	<0.00001
Mean % activity impairment due to IBS symptoms over 8 weeks	31.34 (27.85 to 34.83)	-9.98 (-11.30 to -8.65)	<0.00001	27.57 (24.19 to 30.94)	-7.63 (-8.94 to -6.31)	<0.00001

Data are reported as Mean (range) and time effect (95% CI)

\* Effect for the open-label phase versus the double-blind phase separated into treatment allocation in double-blind phase, adjusted for age, sex, and (where possible, for continuous outcomes) the baseline measure of the outcome

**Table S11.** Outcomes during the follow-up phase.

Outcomes assessed during follow-up phase (ITT population)	N, % (95% CI)
Number of patients reporting adequate relief at the start of the follow-up phase	264/348 75.9%
Percentage of patients who report an increased or maintained	186/251 74.1% (68.3 to 79.2)

treatment benefit at 8 weeks			
Percentage of patients who report having used Enterosgel in the last 8 weeks	203/252	80.6%	(75.2 to 85.0)
Frequency of use of Enterosgel in the last 8 weeks			
Occasionally	52/203	25.6%	(20.1 to 32.1)
1-2 days per week	22/203	10.8%	(7.2 to 15.9)
2-3 days per week	23/203	11.3%	(7.6 to 16.5)
Most days	106/203	52.2%	(45.3 to 59.0)
Percentage of patients who report having used less Loperamide in the last 8 weeks than before the trial	133/250	53.2%	(47.0 to 59.3)

**Table S12.** Adverse Events during the double-blind and open label phase in the safety population; possibly, probably or definitely related to treatment

Adverse event term	Placebo*	Enterosgel*	Open label
Nausea	8	8	0
abdominal pain	4	3	4
bloating	3	6	3
flatulence	0	1	3
Constipation	2	2	2
dry mouth	2	1	0
backpain	0	2	1
loss of appetite	0	2	0
headache	2	2	0
upset stomach/indigestion	0	0	2
burning sensation in throat	1	0	0
diarrhoea and vomiting	1	0	1
increased frequency of defecation	0	1	1
vomiting symptom	0	1	1
diarrhoea	1	0	0
faeces colour: yellow	1	0	0
haemorrhoidal bleeding due to constipation	1	0	0
heartburn	1	0	0

---

increased frequency of defecation	1	0	0
perianal bleeding	1	0	0
right flank pain	1	0	0
suicidal thoughts	1	0	0
thirst post dosing	1	0	0
cough	0	1	0
lethargy	0	1	0
nocturnal diarrhoea	0	1	0
sensation of incomplete emptying of bowel	0	1	0
heartburn	0	0	1
faecal urgency	0	0	1

---

Data presented is for AE terms that are possibly, probably or definitely related to treatment.

\*Double-blind phase